1 / 21

Marie-Louise Newell, Kirsty Little, Madeleine Bunders

Preliminary deliberations towards estimating the burden of HIV disease in children, in the light of need for ART. Marie-Louise Newell, Kirsty Little, Madeleine Bunders (Ghent-IAS Group on HIV infection in women and children). Background.

nishi
Télécharger la présentation

Marie-Louise Newell, Kirsty Little, Madeleine Bunders

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Preliminary deliberations towards estimating the burden of HIV disease in children, in the light of need for ART Marie-Louise Newell, Kirsty Little, Madeleine Bunders (Ghent-IAS Group on HIV infection in women and children)

  2. Background • Mother-to-child transmission of HIV accounts for nearly all HIV infection in children • Although MTCT in the peripartum period can be prevented, the numbers of HIV infected children continues to increase • HIV infection has been associated with an increase in child mortality seen in many areas of sub-Saharan Africa over the past decade • However, there is a lack of data to inform estimates of the number of infected children, the number progressing to serious clinical disease and death and even less data on the number reaching immunological cut-offs for initiation of ARV • The burden of HIV disease in children in terms of the need of care, in particular ARVs, is thus difficult to estimate

  3. Estimating the number of children born to HIV infected women • Population estimates and birth rates taken from UNPOP website to estimate number of deliveries by country • Antenatal HIV prevalences were based on UNAIDS published estimates, Asamoah-Odei 2004, with adjustments based on additional personal information and were used to calculate the numbers of infants born to HIV infected women • In breastfeeding populations in the absence of interventions the rate of MTCT was assumed to be 30% and with PMTCT 20% • In non-breastfeeding populations the assumed rates were 20% and 10% respectively • This thus gives per country an estimated number of infected and uninfected infants

  4. Examples of number of infected and uninfected children W Africa: Burkina Faso, Cote d’Ivoire, Ghana; E Africa: Kenya, Uganda, Rwanda, Ethiopia; Southern Africa: SA, Zimbabwe, Malawi, Zambia, Botswana

  5. Examples 2 of number of infected and uninfected children Asia: Cambodia, India, Thailand Eastern Europe: Ukraine, Moldova, Russian Fed

  6. Estimated number of children alive at selected ages - assumptions • There is a lack of data after age 2, but Spira provides some information up to age 5 year. Thereafter annual mortality is assumed to be constant and at a rate of 10% • Cumulative mortality rates (from Newell et al 2004, and adjusted Spira et al 1999): at age 1 year 35.2%, 2 yr 52.5%,5 yr 75%and 10 yr 85% • It is assumed that for infected children mortality rates in Eastern Europe and Asia are comparable with those estimated for Africa

  7. Number of infected children alive at selected ages – no PMTCT, with PMTCT

  8. Assumptions re the estimated number of children who need ARV on the basis of clinical disease progression • 80% of infants diagnosed with AIDS in their first year of life will have died before age 1 year • The remaining 20% will have the same probability of death as children diagnosed with AIDS in year 2 • Children diagnosed with AIDS after 1 year have a 30% probability of dying within a year • All those diagnosed with AIDS and alive at given ages will require treatment • Cumulative probability of being diagnosed with AIDS by 1 yr: 0.17, by 2 yr 0.28 and by 5 yr 0.35 (from Spira) • Estimated percentage of children diagnosed with AIDS by 1 year of age: 17%, between 1 and 2 years of age 15.4% and between 2 and 5 yr 18.4%

  9. Infected children alive at selected ages needing ARV on the basis of AIDS no PMTCT, with PMTCT

  10. Estimating the number of children eligible for ARV on the basis of CD4% or total lymphocyte counts • Number of children in various CD4 or TLC categories at given ages taken from Dunn et al – HIV Paediatric Prognostic Markers Collaborative Study paper in preparation – with additional information provided by Trinh Duong • These data come from European and American cohort studies and trials, but there are no such data from Africa • WHO below 18mths: TLC <2500 cells and CD4% < 20%; above 18 mths: < 1500 and < 15%

  11. Distribution of CD4% by age HIV Paediatric Prognostic Markers Collaborative Study, 2004, with thanks to Trinh Duong and Di Gibb

  12. Distribution of TLC by age HIV Paediatric Prognostic Markers Collaborative Study, 2004, with thanks to Trinh Duong and Di Gibb

  13. Children at selected ages eligible for ARV on the basis of CD4% - no PMTCT, with PMTCT

  14. Children at selected ages eligible for ARV on the basis of TLC- no PMTCT, with PMTCT

  15. Eligibility on the basis of AIDS, CD4% or TLC at age 2 years, no PMTCT

  16. Eligibility on the basis of AIDS, CD4% or TLC at age 5 years, with PMTCT

  17. Summary • More children would be eligible for treatment on the basis of CD4% than because of AIDS, and the number of children requiring treatment using current cut-offs for TLC is always the lowest • Dunn et al estimate that the number of deaths before reaching the immunological marker value triggering therapy is about 4-6% by age 6 yrs (based on a European-American population) • They also estimate that the cumulative probability of observing a marker value triggering ARV before death increases from 12% (TLC) - 24% (CD4%) at first measurement to 50% (TLC) - 60% (CD4%) 6 years later • In our preliminary model, of children alive at age 2 years 20% would be eligible for ARV on the basis of AIDS, 38% on CD4% and 19% on TLC; at age 5 yrs these percentages are: 22.5%, 26% and 16%

  18. Conclusion • Estimated number of infected children in sub-Saharan Africa (12 countries) ranges from 300,000 to 450,000 per year, of whom an estimated 75,000 to 112,500 will be alive at 5 years of age. Of these about one-quarter would need ARV on the basis of AIDS or CD4% • Numbers in Asia and Eastern Europe are currently small, because the antenatal prevalence is low • This preliminary model has many limitations, but could be made more complex, by for example allowing for differential mortality by age at acquisition of infection and immunological status, but the limiting factor remains the lack of data from Africa and other resource-limited settings, with the associated considerable uncertainty in the basic rates of antenatal seroprevalence, survival of infected children, clinical and immunological disease progression and predictive value of immunological or clinical manifestations

  19. Distribution of CD4 count by age HIV Paediatric Prognostic Markers Collaborative Study, 2004, with thanks to Trinh Duong and Di Gibb

  20. Comparison eligibility AIDS, CD4%, TLC at ages 2 and 5 years; no PMTCT, with PMTCT

More Related